Using AI to spot heart muscle disease on echocardiograms
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study at Mayo Clinic is testing an artificial intelligence (AI) tool that analyzes echocardiograms (ultrasound of the heart) to find early signs of four types of heart muscle disease. If the AI flags a high-risk pattern, doctors can learn whether acting on that alert helps catch the condition sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a doctor, nurse, or other clinician who orders or interprets echocardiograms at a Mayo Clinic site.
- Your patient is 18 or older and is having a full echocardiogram (called a TTE).
- The AI analysis of the echo shows a high risk for one of these conditions: genetic cardiomyopathy, ischemic cardiomyopathy, cardiac amyloidosis, or hypertrophic cardiomyopathy.
- Your patient has NOT already been diagnosed with the condition the AI flagged.
- Your patient is not in hospice care and is expected to live more than one year.
- Your patient has agreed to allow their medical information to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether artificial intelligence can help doctors spot cardiac amyloidosis (a protein buildup in the heart) using heart ultrasound images. If you have signs of a thickened heart wall and possible amyloidosis, this study could help confirm your diagnosis faster and more accurately.
This study tests whether an artificial-intelligence system can help decide who should get a special heart workup for a rare disease called cardiac amyloidosis. If you have signs that make doctors suspect this, the AI-guided ultrasound screening may help find it sooner.
This trial tests an AI program that looks at your heart ultrasound (echocardiogram) to find possible signs of cardiac amyloidosis early. It helps doctors decide if more testing is needed.
This study uses advanced heart scans and AI technology to find early signs of amyloidosis (a protein buildup in the heart) in people with atrial fibrillation. Catching it early may help prevent serious heart problems.
This study uses artificial intelligence (AI) to look at your heart tests (ECG and echo) and find people who might have a specific heart muscle disease called ATTR-CM. The goal is to catch it earlier so treatment can start sooner.
This trial uses an artificial intelligence system to analyze coronary CT scans (CCTA) to help detect various types of heart muscle diseases called cardiomyopathies. The goal is to see if the AI can catch signs of these conditions earlier, possibly leading to quicker diagnosis and treatment.
Hear when a new Ischemic Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.